Dig Dis Sci: 肺移植术后胃轻瘫的危险因素和结果分析

2021-10-09 MedSci原创 MedSci原创

胃轻瘫是最常见的手术后并发症,与糖尿病,病毒感染,风湿病和神经障碍的存在都有关系。胃轻瘫在肺移植后的患者中很常见,患病率为 23-91%。

      胃轻瘫是最常见的手术后并发症,与糖尿病,病毒感染,风湿病和神经障碍的存在都有关系。胃轻瘫在肺移植后的患者中很常见,患病率为 23-91%。肺移植后高发病率的可能原因包括迷走神经损伤、免疫抑制药物的使用以及先前存在的运动障碍的进展。近年来,每年进行的肺移植手术数量一直在增加,2018 年在美国进行了 2,562 例,比前 5 年增加了 31%。因此,进一步准确诊断和治疗胃轻瘫可能会降低慢性肺移植物功能障碍 (CLAD) 的发生率并提高移植后的存活率。本研究旨在确定与肺移植后胃轻瘫新诊断相关的患病率、危险因素。

 

      这是一项针对 2008-2018 年接受肺移植患者的单中心回顾性研究。主要观察结果是移植后 3 年内出现胃轻瘫的频率。次要观察结果包括胃食管反流的新诊断以及胃轻瘫与移植后存活率和无CLAD 存活率之间的关联。多变量逻辑回归用于比较胃轻瘫和胃食管反流的诊断,而多变量 Cox 比例风险模型用于分析胃轻瘫和移植后结果。

 

      研究结果显示在 616名既往无胃轻瘫病史的患者中,107 名 (17.4%) 在移植后 3 年内被诊断为胃排空延迟。在多变量逻辑回归中,黑人(OR 2.16,95% CI 1.18-3.98,p  = 0.013)与胃轻瘫的新诊断显着相关。年龄、性别、糖尿病病史、结缔组织病、移植类型、肾功能和体重指数不能预测移植后胃轻瘫。同时,胃轻瘫与 CLAD 显着相关(HR 1.76,95% CI 1.20–2.59,p= 0.004),但与总体死亡率无关(HR 1.16,p= 0.43)。

 

      本项研究的结果说明虽然肺移植后胃轻瘫很常见,但仍难以预测哪些患者会在移植后出现这些并发症。在调整相关混杂因素后,黑人患者更有可能被诊断为胃轻瘫,而且胃轻瘫与 CLAD 风险增加有关。

 

 

原始出处:

John W. Blackett. Et al. Risk Factors and Outcomes for Gastroparesis After Lung Transplantation. Digestive Diseases and Sciences.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999013, encodeId=44d8199901389, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Feb 06 14:31:57 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013724, encodeId=15532013e240a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 20 04:31:57 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060167, encodeId=abdc106016e41, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a85549889, createdName=ms2000000182667314, createdTime=Wed Oct 13 16:20:34 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059323, encodeId=52fd105932359, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ad2152218, createdName=朵小朵朵, createdTime=Mon Oct 11 07:13:27 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059271, encodeId=51b810592e144, content=X5系去啦佛具体点君威尼斯水城, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 10 21:56:07 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2022-02-06 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999013, encodeId=44d8199901389, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Feb 06 14:31:57 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013724, encodeId=15532013e240a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 20 04:31:57 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060167, encodeId=abdc106016e41, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a85549889, createdName=ms2000000182667314, createdTime=Wed Oct 13 16:20:34 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059323, encodeId=52fd105932359, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ad2152218, createdName=朵小朵朵, createdTime=Mon Oct 11 07:13:27 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059271, encodeId=51b810592e144, content=X5系去啦佛具体点君威尼斯水城, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 10 21:56:07 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999013, encodeId=44d8199901389, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Feb 06 14:31:57 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013724, encodeId=15532013e240a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 20 04:31:57 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060167, encodeId=abdc106016e41, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a85549889, createdName=ms2000000182667314, createdTime=Wed Oct 13 16:20:34 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059323, encodeId=52fd105932359, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ad2152218, createdName=朵小朵朵, createdTime=Mon Oct 11 07:13:27 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059271, encodeId=51b810592e144, content=X5系去啦佛具体点君威尼斯水城, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 10 21:56:07 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-13 ms2000000182667314

    有用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1999013, encodeId=44d8199901389, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Feb 06 14:31:57 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013724, encodeId=15532013e240a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 20 04:31:57 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060167, encodeId=abdc106016e41, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a85549889, createdName=ms2000000182667314, createdTime=Wed Oct 13 16:20:34 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059323, encodeId=52fd105932359, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ad2152218, createdName=朵小朵朵, createdTime=Mon Oct 11 07:13:27 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059271, encodeId=51b810592e144, content=X5系去啦佛具体点君威尼斯水城, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 10 21:56:07 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-11 朵小朵朵

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1999013, encodeId=44d8199901389, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Feb 06 14:31:57 CST 2022, time=2022-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013724, encodeId=15532013e240a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Aug 20 04:31:57 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060167, encodeId=abdc106016e41, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a85549889, createdName=ms2000000182667314, createdTime=Wed Oct 13 16:20:34 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059323, encodeId=52fd105932359, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ad2152218, createdName=朵小朵朵, createdTime=Mon Oct 11 07:13:27 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059271, encodeId=51b810592e144, content=X5系去啦佛具体点君威尼斯水城, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 10 21:56:07 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-10 查查佳佳

    X5系去啦佛具体点君威尼斯水城

    0

相关资讯

Nat Commun:采用负压通气异位肺灌注可延长标准供体肺的移植

肺移植仍然是治疗终末期肺病的最佳长期治疗方案。尽管肺移植率不断提高,主要是通过增加使用循环死亡捐赠者(DCD)的捐赠,但传统上移植等待名单的死亡率一直相对稳定。

回顾性研究:肺移植后发生静脉血栓栓塞的危险因素有哪些

肺移植后静脉血栓栓塞(VTE)是比较常见的,并与移植后生存恶化相关。那么肺移植后发生静脉血栓栓塞的危险因素有哪些呢?

JHLT:基于体外膜氧合技术,肺动脉高压 患者具有较低的移植率?

肺移植的供体分配会严重影响等待肺移植病人的未来,如何分配才能让更多的人收益?

Eur Respir J:血清中小HDL颗粒水平与死亡或肺移植呈负相关

IPF患者血清中较高的S-HDLPNMR水平与GAP指数以及较低的死亡率或肺移植呈负相关。这些结果支持S-HDLPNMR可能改变IPF患者死亡风险的假设。

J heart Lung Transplant:间质性肺疾病肺移植中供体-受体大小匹配的简化策略

供体-受体尺寸匹配已多次被报道可以改善肺移植(LTx)的预后。然而,在实践中有很大的可变性,最佳的尺寸匹配策略还没有定义。

Lancet Respirat Med:肺内微生物群状况可预测肺移植患者预后!

在慢性肺部疾病中常见呼吸微生物群改变,与肺功能下降有关,还与疾病进展有关。肺移植后呼吸微生物群变化的临床意义,特别是与慢性肺同种异体移植功能障碍(CLAD)的发展有关的临床意义尚不清楚。本研究旨在评估